Board Meetings for SUNPHARMA
Detailed list of historic and upcoming board meetings.
| Symbol | Company | Meeting Date | Purpose | Description | Links |
|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 02 Nov 2021 | Financial Results | To consider and approve the financial results for the period ended September 30, 2021 | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 30 Jul 2021 | Financial Results | To consider and approve the Unaudited Standalone and Consolidated financial results for the quarter ended Jun 30, 2021 | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 27 May 2021 | Financial Results/Dividend | To consider and approve the audited financial results for the quarter and year ended March 31, 2021 and recommendation of final dividend for the year ended March 31, 2021. | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 29 Jan 2021 | Financial Results | To consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2020 | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 03 Nov 2020 | Financial Results | To consider and approve the Unaudited Standalone and Consolidated financial results of the Company for the quarter and half year ended September 30, 2020 | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 31 Jul 2020 | Financial Results | To consider and approve the Unaudited Standalone and Consolidated Financial Results financial results for the quarter ended Jun 30, 2020 | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 27 May 2020 | Financial Results/Dividend | To consider and approve Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2020 and to consider recommendation of final dividend for the year ended March 31, 2020 subject to the approval of the shareholders at the ensuing Annual General Meeting. | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 17 Mar 2020 | Buyback | To consider, inter alia, the proposal for buy-back of fully paid-up equity shares of the Company, which would include maximum amount, maximum number of equity shares, mode of buy-back and other matters incidental thereto in accordance with the provisions of Section 68, 69 and 70 of the Companies Act,2013, read with rules made thereto and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018.In this connection, as per the Company's code of conduct for prevention of insider trading, the trading window for dealing or trading in securities of the Company will remain closed with immediate effect for all directors, designated persons and insiders and shall re-open after the expiry of 48 hours after the conclusion of the aforesaid Board Meeting.proposal buyback for equity shares | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 06 Feb 2020 | Financial Results | To inter alia consider and approve the financial results for the period ended December 31, 2019 | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 06 Feb 2020 | Dividend | Consider declaration of Interim Dividend on the equity shares of the Company, for the Financial Year 2019-2020. | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 07 Nov 2019 | Financial Results | To consider and approve the financial results for the period ended September 30, 2019 | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 13 Aug 2019 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 28 May 2019 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2019 and dividend | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 12 Feb 2019 | Financial Results | To consider and approve the financial results for the period ended December 31, 2018 | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 13 Nov 2018 | Financial Results | To consider and approve the financial results for the period ended September 30, 2018. Notice of Board Meeting for consideration and approval of Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2018 and intimation of dates of Window Closure for Trading by Designated persons. |